Antibody drug conjugates are a promising class of therapeutic drugs accepted worldwide for the treatment of cancer. ADCs comprise monoclonal antibodies that are conjugated to the cytotoxic payload via linkers that are directed towards the targeted antigen expressed on the tumor cell surface—resulting in toxicity and initiating killing action. The Antibody drug conjugate market provides